We work to advance human health and wellness by delivering vaccines and innovative medicines that improve the quality of life

The MSD Sales and Marketing office was first established in 1993. Our business focuses on innovation and scientific excellence to deliver prescription medicines, vaccines, and biologic therapies that can help millions around the world.

Our therapeutic areas of focus include cancer, diabetes, vaccines, cardiovascular, and hospital acute care. Cancer is a complex disease and one of the leading causes of death worldwide. With annual cancers expected to rise to 22 million within the next two decades, MSD is investing significant resources to develop innovative oncology medicine to help people with cancer. In the area of diabetes, we collaborate with academic and industry partners to help advance the care of patients with diabetes.

Vaccines are one of the greatest public health success stories in history, and MSD has played its part in that story. We are dedicated to the complex business of researching and producing vaccines. We are also strategically focused on acute care within the larger hospital setting. We believe our greatest impact can be in addressing significant unmet medical needs and opportunities to improve patient care while managing costs.

Pharmaceutical innovation must continue as the world is still plagued with devastating diseases like cancer, Alzheimer’s, and cardio-metabolic disease. At MSD, we are on a quest for cures – that’s our calling.

As a global healthcare leader, we have a central purpose: to help people live longer, healthier and more productive lives. Whether it is by inventing breakthrough medicines and vaccines that address critical areas of growing medical need, improving access to health care and improving awareness and education about diseases, protecting the environment or engaging employees, we are committed to making the world a better place today and for generations to come.

“We are committed to making the world a better place today and for generations to come.”

Kenneth C. Frazier